Misplaced Pages

Richard Barker (businessman): Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editNext edit →Content deleted Content addedVisualWikitext
Revision as of 20:27, 25 August 2024 editProf Richard Barker (talk | contribs)4 edits Updated Richard Barker's career details, including his current and past board memberships, and added his role as a visiting professor at King's College London. Adjusted references and formatting for accuracy.Tags: Reverted possible BLP issue or vandalism COI template removed references removed Visual edit: Switched← Previous edit Revision as of 20:34, 25 August 2024 edit undo2NumForIce (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers5,222 editsm Rollback edit(s) by Prof Richard Barker (talk): WP:Neutral point of view, contains a bit of MOS:PUFFERY, also unWP:reliable sources (RW 16.1)Tags: RW Rollback Disambiguation links addedNext edit →
Line 1: Line 1:
{{Short description|Healthcare leader and precision medicine expert}} {{Short description|British healthcare consultant}}
{{Advert|date=July 2020}}
'''Prof. Richard Barker''' {{post-nominals|country=GBR|OBE|FFPM}} is a ] leader known for his forward-thinking approach and innovative contributions to the field. He co-founded and chairs Metadvice<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-25}}</ref>, a company developing AI-driven healthcare platforms. He also established New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-25}}</ref> and is the Founding Director of the ]’s ]<ref name="CASMI">{{cite web |title=Dr Richard Barker OBE |url=http://casmi.org.uk/dr-richard-barker/ |url-status=dead |archiveurl=https://archive.today/20130423193417/http://casmi.org.uk/dr-richard-barker/ |archivedate=2013-04-23 |accessdate=2013-02-11 |publisher=CASMI}}</ref> in collaboration with University College London. Barker is the chair of the advisory board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-25}}</ref> and a co-founder and board member of 2BWell<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-25}}</ref>, a mental health initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at King’s College London.
'''Richard William Barker''' {{post-nominals|country=GBR|OBE|FFPM}} is the Founder of New Medicine Partners and Founding Director of the ] — University College of London ] (CASMI).<ref name=CASMI>{{cite web|title=Dr Richard Barker OBE|url=http://casmi.org.uk/dr-richard-barker/|publisher=CASMI|accessdate=2013-02-11|url-status=dead|archiveurl=https://archive.today/20130423193417/http://casmi.org.uk/dr-richard-barker/|archivedate=2013-04-23}}</ref>




{{Infobox person {{Infobox person
| name = Prof. Richard Barker | name = Richard William Barker
| occupation = Healthcare Leader and Precision Medicine and Longevity Expert | occupation = Life Sciences and Healthcare leader
| known_for = Founder of New Medicine Partners, Co-founder of Metadvice, and Founding Director of the University of Oxford’s Centre for Sustainable Medical Innovation. Chair of the Advisory Board at NWPharmaTech and a leader in advancing precision medicine, healthcare innovation, and healthy longevity initiatives. | known_for = Founder of New Medicine Partners and Founding Director of the University of Oxford.
}} }}


== Early life == == Early life ==
Barker was born in South ] and attended Alleyn's School<ref>{{Cite web|title=Home - Alleyn's School|url=https://www.alleyns.org.uk/|access-date=2024-08-25|website=www.alleyns.org.uk|language=en-US}}</ref> in Dulwich, London. Barker was born in South ] prominent family relatives such as Araminta march socialite, ''Mr.'' Clifford Barker a former Philip green associate and Kia Harriette his only child. He attended ]<ref>{{Cite web|title=Home - Alleyn's School|url=https://www.alleyns.org.uk/|access-date=2021-10-05|website=www.alleyns.org.uk|language=en-US}}</ref> in ].


== Higher education ==
Barker was educated at ],<ref>{{Cite web|title=Homepage|url=http://www.exeter.ox.ac.uk/|access-date=2021-10-05|website=Exeter College|language=en-GB}}</ref> where he received a ] in chemistry. Following completion of his degree, he researched biological applications of ]s in pursuit of an Oxford<ref>{{Cite web|title=University of Oxford|url=https://www.ox.ac.uk/|access-date=2021-10-05|website=www.ox.ac.uk}}</ref> ] degree, followed by post-doctoral studies in ] and ].<ref>{{Cite web|url=http://www.hm.edu/en/|title=Munich University MUAS - HM Hochschule München University of Applied Sciences}}</ref><ref>{{Cite web|last=Leeds|first=University of|title=University of Leeds|url=https://www.leeds.ac.uk/|access-date=2021-10-05|website=www.leeds.ac.uk|language=en}}</ref>


== Education == ==Career==
Barker's business career has included work in both Europe and the US.<ref name=Bloomberg>{{cite web|title=Richard W. Barker D.Phil., B.A., M.A.|url=http://investing.businessweek.com/research/stocks/people/person.asp?personId=436430&ticker=ICO:CN&previousCapId=23112550&previousTitle=ICO%20THERAPEUTICS%20INC|publisher=Investing.businessweek.com|accessdate=2013-02-11}}{{dead link|date=April 2023|bot=medic}}{{cbignore|bot=medic}}</ref> He worked for ]<ref>{{Cite web|title=McKinsey & Company {{!}} Global management consulting|url=https://www.mckinsey.com/|access-date=2021-10-05|website=www.mckinsey.com|language=en}}</ref> between 1980 and 1993, where he headed the European Healthcare practice<ref>http://www.mckinsey.com/client_service/healthcare_systems_and_services {{Webarchive|url=https://web.archive.org/web/20130424150911/http://www.mckinsey.com/client_service/healthcare_systems_and_services |date=2013-04-24 }}</ref> and advised UK, Swiss and US pharmaceutical companies. He also helped establish ']',<ref>{{Cite web|title=London First|url=https://www.londonfirst.co.uk/|access-date=2021-10-05|website=www.londonfirst.co.uk}}</ref> a public/private initiative that aims to enhance London's status as a global city. As General Manager of ]'s healthcare business,<ref>{{Cite web|url=http://www-935.ibm.com/industries/uk/en/healthcare/|title=Healthcare Technology Solutions & Services}}</ref> between 1993 and 1996 he launched ], one of the earliest Internet healthcare applications.<ref></ref> At ],<ref>{{Cite web|url=http://www.nndb.com/company/216/000123844/|title=Chiron Corporation}}</ref> a multinational bio-technology firm that was acquired by ] in 1996, he headed the diagnostics business, which brought the latest ] to market.{{cn|date=May 2022}} He subsequently served as a chairman and chief executive of Molecular Staging,<ref>http://molecularstaging.aussieblogs.com.au {{Webarchive|url=https://web.archive.org/web/20130420114935/http://molecularstaging.aussieblogs.com.au/ |date=2013-04-20 }}</ref> whose ] enables ] on rare ].<ref>http://molecularstaging.aussieblogs.com.au/technology/ {{Webarchive|url=https://web.archive.org/web/20140125225325/http://molecularstaging.aussieblogs.com.au/technology/ |date=2014-01-25 }}</ref>
Barker studied chemistry at ],<ref>{{Cite web|title=Homepage|url=http://www.exeter.ox.ac.uk/|access-date=2024-08-25|website=Exeter College|language=en-GB}}</ref> earning a bachelor's degree. He pursued research on the biological applications of ] for his PhD in Philosophy at ], followed by post-doctoral studies in Munich, Germany, and ], England.


On returning to the UK, he headed the ] (ABPI) for six years between 2004 and 2011<ref name=PMLive>{{cite web|title=Former ABPI head Richard Barker joins Aegate as senior adviser|date=9 January 2012|url=http://www.pmlive.com/pharma_news/abpi_richard_barker_aegate_michael_peace_355981|publisher=Pmlive.com|accessdate=2013-02-11}}</ref> and initiated policy programs in stratified medicine,<ref>try-info/future/Pages/personalised-medicines.aspx</ref> while also launching frameworks for translational partnerships between academia and industry.<ref>http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx {{Webarchive|url=https://web.archive.org/web/20130407085850/http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx |date=2013-04-07 }}</ref> He also formed and chaired Stem Cells for Safer Medicines,<ref>http://www.sc4sm.org {{Webarchive|url=https://web.archive.org/web/20220617163230/https://www.sc4sm.org/ |date=2022-06-17 }}</ref> a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.


In 2012 with his colleagues at Oxford and UCL, he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit.<ref>http://www.casmi.org.uk {{Webarchive|url=https://web.archive.org/web/20180625202006/http://casmi.org.uk/ |date=2018-06-25 }}</ref> As Founding Director of CASMI he held an associate professorship in Oxford University's Medical Division from 2012 to 2017.<ref>{{Cite web|title=UCL School of Life and Medical Sciences — CASMI|date=14 August 2018|url=https://www.ucl.ac.uk/school-life-medical-sciences/research/casmi}}</ref>
==Career==
Barker's career has spanned Europe and the US, including work with ] from 1980 to 1993, where he led the European healthcare practice. He contributed to the founding of ']', a public/private initiative to enhance London's global status. At ], he managed the global healthcare business from 1993 to 1996, launching Health Village, an early Internet healthcare application. He later worked at ], heading the diagnostics business, and served as chairman and CEO of Molecular Staging, focusing on ] amplification technology.


He chairs the South London Academic Health Science Network,<ref>{{Cite web|url=http://www.kingshealthpartners.org/info/southlondonahsn|title = About Us &#124; King's Health Partners &#124; London}}</ref> which aims to improve the quality and consistency of care in that part of the ] (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.<ref>{{Cite web|url=https://www.gov.uk/government/publications/academic-health-science-networks-request-for-expressions-of-interest-to-create-ahsns--2|title = &#91;Withdrawn&#93; Academic health science networks: Request for expressions of interest to create AHSNs}}</ref>
Returning to the UK, Barker led the ] (ABPI)<ref>{{cite web |title=ABPI Honorary Fellows |url=https://www.bps.ac.uk/about/who-we-are/honorary-fellows-directory/profile?ID=762b7f3a-8d90-e611-80d8-00155d146335&product=%7Chonorary |access-date=2024-08-25}}</ref> from 2004 to 2011, supporting initiatives in ] and translational partnerships between academia and industry. He co-founded the ] (CASMI) in 2012 and held an associate professorship at ] until 2017. Barker previously chaired the South London Academic Health Science Network and the charity International Health Partners<ref>{{cite web |title=International Health Partners |url=https://www.ihpuk.org |access-date=2024-08-25}}</ref>.


Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters. <ref>{{Cite web|title=CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934|url=https://www.sec.gov/Archives/edgar/data/0001690080/000121390020044354/ea132067-8k_180lifescien.htm|access-date=2021-12-16}}</ref>
Currently, Barker is the chairman and co-founder of Metadvice<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-25}}</ref>, which develops AI-driven healthcare platforms. He is also the founder and chairman of New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-25}}</ref>, where he advises on ] and health. As a recognized futurist in healthcare, Barker serves as the chair of the advisory board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-25}}</ref> and is a co-founder and board member of 2BWell<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-25}}</ref>, a mental health chatbot initiative supporting Ukrainians. Additionally, he is a visiting professor in Precision Population Health at ], reflecting his ongoing commitment to advancing healthcare innovation and ].


He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.<ref>{{Cite web|url=http://www.ihpuk.org/our-team/4594052457|title=ABOUT - IHP|website=www.ihpuk.org|language=en|access-date=2018-06-10}}</ref>

He has also founded and directed New Medicine Partners, an advisory company that creates strategies for precision medicine and precision health to advance a healthy lifespan.<ref>{{Cite web|url=https://www.newmedicine.io|title=Welcome to New Medicine Partners|website=New Medicine Partners|language=en-GB|access-date=2018-06-10}}</ref> He is also the Founding Director of ], a global healthcare company developing an AI-driven platform for clinical decision making.<ref>{{Cite web|title=Metadvice :: Team {{!}} Leaders {{!}} Experts|url=https://www.metadvice.com/team3.php|access-date=2021-04-07|website=www.metadvice.com}}</ref>


== Board memberships == == Board memberships ==
* ]<ref>{{cite web|url=http://www.innovationdebate.com/debate/panelists/dr-richard-barker/ |title=Dr Richard W. Barker: The Innovation Debate 2012 |publisher=Innovationdebate.com |date=2012-11-20 |accessdate=2013-02-19}}</ref>
Richard Barker is the Founder and Chairman of New Medicine Partners<ref>{{cite web |title=New Medicine Partners |url=https://newmedicine.io/ |access-date=2024-08-25}}</ref>, Co-founder and Chairman of Metadvice<ref>{{cite web |title=Metadvice |url=https://www.metadvice.com/ |access-date=2024-08-25}}</ref>, Chair of the Advisory Board at NWPharmaTech<ref>{{cite web |title=NWPharmaTech |url=https://nwpharmatech.com/ |access-date=2024-08-25}}</ref>, and Co-founder and Board Member of 2BWell<ref>{{cite web |title=2BWell |url=https://www.2bwell.org/ |access-date=2024-08-25}}</ref>. He has previously served as Chairman and CEO of Molecular Staging, chaired the South London Academic Health Science Network, contributed to International Health Partners<ref>{{cite web |title=International Health Partners |url=https://www.ihpuk.org/ |access-date=2024-08-25}}</ref>, and served on the board of Celgene Corporation.



== Awards == == Awards ==
Richard Barker was appointed ] (OBE) in 2011 for his contributions to the ]. In 2021, he was awarded an ] by the ], recognizing his significant impact on the field. In 2011 Professor Richard Barker was awarded ] for his services to the ] by the ].<ref>{{Cite web|date=2011-12-30|title=Honours: Order of the British Empire, Civil - OBE|url=https://www.independent.co.uk/news/uk/home-news/honours-order-british-empire-civil-obe-6283146.html|access-date=2021-04-07|website=The Independent|language=en}}</ref> In 2021 he was awarded Honorary Fellowship of the ].



== Published works == == Published works ==
;Books ;Books
* Barker, Richard (2010). ''2030: The Future of Medicine'', Oxford University Press, 118 pages. {{ISBN|978-0199600663}} * Barker, Richard (2010). ''2030: the Future of Medicine'', Oxford University Press, 118 pages. {{ISBN|978-0199600663}}
*Barker, Richard (2016). ''Bioscience — Lost in Translation?,'' Oxford University Press, 226 pages. {{ISBN|978-0198737780}} *Barker, Richard (2016). ''Bioscience — Lost in Translation?,'' Oxford University Press, 226 pages. {{ISBN|978-0198737780}}



;Selected Articles ;Selected Articles
* Barker, Richard W.; and Sarah Garner. "Adaptive Drug Development and Licensing", ''Regulatory Rapporteur'', Vol. 9, No. 10, p. 13, October 2012. * Barker, Richard W.; and Sarah Garner. "Adaptive drug development and licensing", ''Regulatory Rapporteur'', Vol 9, No 10, page 13, October 2012.
* Barker, Richard. "A Flexible Blueprint for the Future of Drug Development", ''The Lancet'', Vol. 375, Issue 9712, pp. 357–359, 30 January 2010. * Barker, Richard. "A flexible blueprint for the future of drug development", ''The Lancet'', Volume 375, Issue 9712, pages 357–359, 30 January 2010.
*See . *See .



==References== ==References==
Line 56: Line 56:
] ]
] ]
]
]
]
]
]
]
]
]
]
]

Revision as of 20:34, 25 August 2024

British healthcare consultant
This article contains promotional content. Please help improve it by removing promotional language and inappropriate external links, and by adding encyclopedic text written from a neutral point of view. (July 2020) (Learn how and when to remove this message)

Richard William Barker OBE FFPM is the Founder of New Medicine Partners and Founding Director of the University of Oxford — University College of London Centre for the Advancement of Sustainable Medical Innovation (CASMI).

Richard William Barker
Occupation(s)Life Sciences and Healthcare leader
Known forFounder of New Medicine Partners and Founding Director of the University of Oxford.

Early life

Barker was born in South London prominent family relatives such as Araminta march socialite, Mr. Clifford Barker a former Philip green associate and Kia Harriette his only child. He attended Alleyn's School in Dulwich, London.

Higher education

Barker was educated at Exeter College, Oxford, where he received a bachelor's degree in chemistry. Following completion of his degree, he researched biological applications of magnetic resonance techniques in pursuit of an Oxford DPhil degree, followed by post-doctoral studies in Munich, Germany and Leeds, England.

Career

Barker's business career has included work in both Europe and the US. He worked for McKinsey between 1980 and 1993, where he headed the European Healthcare practice and advised UK, Swiss and US pharmaceutical companies. He also helped establish 'London First', a public/private initiative that aims to enhance London's status as a global city. As General Manager of IBM's healthcare business, between 1993 and 1996 he launched Health village, one of the earliest Internet healthcare applications. At Chiron, a multinational bio-technology firm that was acquired by Novartis in 1996, he headed the diagnostics business, which brought the latest immunodiagnostics to market. He subsequently served as a chairman and chief executive of Molecular Staging, whose genome amplification technology enables gene sequencing on rare DNA samples.

On returning to the UK, he headed the Association of the British Pharmaceutical Industry (ABPI) for six years between 2004 and 2011 and initiated policy programs in stratified medicine, while also launching frameworks for translational partnerships between academia and industry. He also formed and chaired Stem Cells for Safer Medicines, a public/private partnership formed to develop new approaches to testing potential new medicines for toxicity.

In 2012 with his colleagues at Oxford and UCL, he founded CASMI to develop, test and promote new models of medical innovation, including adaptive licensing, cell therapy regulation and a combination of therapeutic and diagnostic products to focus treatments on the patients most likely to benefit. As Founding Director of CASMI he held an associate professorship in Oxford University's Medical Division from 2012 to 2017.

He chairs the South London Academic Health Science Network, which aims to improve the quality and consistency of care in that part of the National Health Service (NHS), and to facilitate innovations emerging from academic and industrial research into NHS application.

Effective as of December 18, 2020, he resigned from the Board of Directors of 180 Life Sciences Corp, because of other commitments that would not allow him to spend sufficient time on Company matters.

He chairs the charity International Health Partners that brings donated medicines to developing countries, crisis situations and refugee camps.

He has also founded and directed New Medicine Partners, an advisory company that creates strategies for precision medicine and precision health to advance a healthy lifespan. He is also the Founding Director of Metadvice, a global healthcare company developing an AI-driven platform for clinical decision making.

Board memberships

Awards

In 2011 Professor Richard Barker was awarded the Order of the British Empire for his services to the pharmaceutical industry by the Queen Elizabeth II. In 2021 he was awarded Honorary Fellowship of the Faculty of Pharmaceutical Medicine.

Published works

Books
  • Barker, Richard (2010). 2030: the Future of Medicine, Oxford University Press, 118 pages. ISBN 978-0199600663
  • Barker, Richard (2016). Bioscience — Lost in Translation?, Oxford University Press, 226 pages. ISBN 978-0198737780
Selected Articles
  • Barker, Richard W.; and Sarah Garner. "Adaptive drug development and licensing", Regulatory Rapporteur, Vol 9, No 10, page 13, October 2012.
  • Barker, Richard. "A flexible blueprint for the future of drug development", The Lancet, Volume 375, Issue 9712, pages 357–359, 30 January 2010.
  • See CASMI website.

References

  1. "Dr Richard Barker OBE". CASMI. Archived from the original on 2013-04-23. Retrieved 2013-02-11.
  2. "Home - Alleyn's School". www.alleyns.org.uk. Retrieved 2021-10-05.
  3. "Homepage". Exeter College. Retrieved 2021-10-05.
  4. "University of Oxford". www.ox.ac.uk. Retrieved 2021-10-05.
  5. "Munich University MUAS - HM Hochschule München University of Applied Sciences".
  6. Leeds, University of. "University of Leeds". www.leeds.ac.uk. Retrieved 2021-10-05.
  7. "Richard W. Barker D.Phil., B.A., M.A." Investing.businessweek.com. Retrieved 2013-02-11.
  8. "McKinsey & Company | Global management consulting". www.mckinsey.com. Retrieved 2021-10-05.
  9. http://www.mckinsey.com/client_service/healthcare_systems_and_services Archived 2013-04-24 at the Wayback Machine
  10. "London First". www.londonfirst.co.uk. Retrieved 2021-10-05.
  11. "Healthcare Technology Solutions & Services".
  12. EBSCOhost Connection
  13. "Chiron Corporation".
  14. http://molecularstaging.aussieblogs.com.au Archived 2013-04-20 at the Wayback Machine
  15. http://molecularstaging.aussieblogs.com.au/technology/ Archived 2014-01-25 at the Wayback Machine
  16. "Former ABPI head Richard Barker joins Aegate as senior adviser". Pmlive.com. 9 January 2012. Retrieved 2013-02-11.
  17. try-info/future/Pages/personalised-medicines.aspx
  18. http://www.abpi.org.uk/industry-info/future/Pages/collaboration.aspx Archived 2013-04-07 at the Wayback Machine
  19. http://www.sc4sm.org Archived 2022-06-17 at the Wayback Machine
  20. http://www.casmi.org.uk Archived 2018-06-25 at the Wayback Machine
  21. "UCL School of Life and Medical Sciences — CASMI". 14 August 2018.
  22. "About Us | King's Health Partners | London".
  23. "[Withdrawn] Academic health science networks: Request for expressions of interest to create AHSNs".
  24. "CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934". Retrieved 2021-12-16.
  25. "ABOUT - IHP". www.ihpuk.org. Retrieved 2018-06-10.
  26. "Welcome to New Medicine Partners". New Medicine Partners. Retrieved 2018-06-10.
  27. "Metadvice :: Team | Leaders | Experts". www.metadvice.com. Retrieved 2021-04-07.
  28. "Dr Richard W. Barker: The Innovation Debate 2012". Innovationdebate.com. 2012-11-20. Retrieved 2013-02-19.
  29. "Honours: Order of the British Empire, Civil - OBE". The Independent. 2011-12-30. Retrieved 2021-04-07.
Categories: